(Reuters) – AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.
The company said the combination treatment reduced the risk of disease progression or death by 76% compared with usage of abiraterone alone.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D’Souza)